Cancer cells constantly evolve in response to acute and chronic stimuli.
Drug resistance is one product of this evolution, as cells quickly adopt drug-resistant states when exposed to pharmacological treatments.
How cancer cells reach drug resistance remains unclear, so researchers from the California Institute for Technology implemented a multi-omics approach for characterizing drug resistance mechanisms using IsoPlexis’ single-cell intracellular proteomics and metabolomics.
Download this research summary to find out how the CalTech team used predictive single-cell functional proteomic and metabolic assays to investigate changing cellular states in melanoma cells for the development of improved targeted therapies.
Offered Free by: Isoplexis
See All Resources from: Isoplexis